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FOCUS ON YALE MEDICINE
New Frontiers in Molecular Pharmacology and
Medicine: A Celebration
Ellen Wittmack and Wenya Linda Bi
Yale University School ofMedicine, New Haven, Connecticut
On October 24, 2003, the Yale School
of Medicine inaugurated its new wing for
the Department of Pharmacology with a
star-studded symposium titled "New
Frontiers in Molecular Pharmacology and
Medicine." In the world of academia, this
is as close as one gets to red carpet Oscar
quality spectatorship. The roster began
with Tony Hunter of the Salk Institute,
Joan Steitz ofYale, Jack Dixon of UCSD,
Robert Weinberg of MIT, Joseph
Goldstein of University of Texas
Southwestern and winner of the 1985
Nobel Prize in Medicine, Stuart Schreiber
of Harvard, and ended with Paul
Greengard of Rockefeller University and
winner of the 2000 Nobel Prize in
Physiology.
HISTORICAL PERSPECTIVES ON
YALE PHARMACOLOGY
The Department of Pharmacology at
Yale has a renowned history since its
inception in the 1940s by William Salter.
Most notably, it has led the world in the
study of cancer chemotherapy and neu-
ropharmacology. Indeed, modem cancer
chemotherapy took flight at Yale in 1942
when Alfred Gilman and Louis Goodman
discovered the first anticancer drug for
lymphoma when they demonstrated the
effects of nitrogen mustard in reducing
transplanted lymphosarcoma in mice
(Gilman et al., 1963).
In 1953, Arnold Welch came to Yale
from Oxford to become the departmental
chair. He took over an anemic department
and began to recruit young scientists who
would prove to be the best in the country.
John Vane shared the Nobel Prize in 1982
for his work on prostaglandins and prosta-
cyclin and the mechanism of action of
aspirin. William Prusoff discovered the
first specific antiviral drug to be used in
man, 5-Iododeoxyuridine (IUdR) for the
treatment of ocular herpes and later found
the first drug against human immunodefi-
ciency virus, 3'-deoxythymidin-2'-ene
(d4T) (Lin TS et al., 1987). In neurophar-
macology, Jack Cooper, Robert Roth, and
Floyd Bloom led the research effort and
wrote the Biochemical Basis of
Neuropharmacology in 1970, a book that
is in its Ninth Edition and can still be
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In 1967, Murdoch Ritchie was
appointed Chairman ofthe department and
worked in collaboration with William
Douglas on the firing properties of non-
medullated afferent fibers and with Paul
Greengard on the mode of action of local
anesthetics. Greengard went on to share
the Nobel Prize in 2000 with Arvid
Carlsson and Eric Kandel for his work on
dopamine and other "slow" transmitters
which act by protein phosphorylation and
allow signal transduction in the nervous
system. Alan Sartorelli, John Perkins, and
Len Kaczmarek also served in as chairmen
of the department until the arrival of
Joseph Schlessinger in 2001.
OLD THEMES, NEW IDEAS
As Alan Sartorelli puts it,
"Pharmacology is the study of drugs
but that can be accomplished in many,
almost any, ways." Indeed, Yale
Pharmacology is becoming increasingly
multidisciplinary in this goal. The depart-
ment today emphasizes a number of dif-
ferent areas including neurochemistry,
neurophysiology, psychopharmacology,
viral and microbial chemotherapy and
clinical pharmacology. In addition, there is
ongoing research into the mechanisms
behind signal transduction, carcinogene-
sis, drug resistance, and differentiation.
Joseph Schlessinger joined the
Pharmacology department as Chairman in
2001. Schlessinger heads a team of
dynamic researchers focusing on many
different areas of pharmacology - many
of whom use signaling in order to address
questions in either cancer or neuropharma-
cology. Investigators involved in signaling
are Anton Bennett, William Sessa, Elias
Lolis, and Barbara Ehrlich. Bennett is
interested in the role protein tyrosine phos-
phatases play in cellular processes such as
mitogenesis, apoptosis, cell movement
and differentiation. Sessa focuses on how
endothelial nitric oxide synthase is regu-
lated in the context of normal physiology
and in disease and the application of pro-Wittmack and Bi: History of Yale pharmacology 135
teomics to discover new targets to regulate
blood vessel function. The structure-func-
tion relationships of chemokines is being
investigated by Lolis, while Ehrlich is
interested in the mechanisms behind cell
regulation ofintracellular calcium concen-
tration.
In the area of signaling and neu-
ropharmacology, Angus Nairn works on
the characterization of the basal ganglia
phosphoprotein DARPP-32 and the possi-
bility ofdeveloping drugs that specifically
affect phosphoproteins or their targets. Ya
Ha uses x-ray diffraction to study how
membrane proteins carry out complex bio-
logical functions on the surface of neu-
ronal cells and how changes in these pro-
teins cause neurodegeneration. Jim Howe
studies glutamate receptors, Gary Rudnick
focuses on neurotransmitter transport, and
Len Kaczmarek's research aims to under-
stand the nature of the biochemical
changes that occur in neurons. Priscilla
Dannies examines the process by which
protein hormones and neuropeptides are
concentrated into secretory granules.
Among the Pharmacology faculty
members that study cancer are Karen
Anderson, David Calderwood, Yung-Chi
Cheng, andAlan Sartorelli. Anderson does
research that interfaces signaling and can-
cer by developing an understanding of
enzymatic reactions and receptor-ligand
interactions at a molecular level.
Calderwood, the newest recruit to
Pharmacology, studies molecular control
of integrin signaling as intergrins regulate
cell adhesion, growth and migration.
Cheng focuses on cancer and viral
chemotherapy and studies the functional
roles and properties of virus-specific pro-
teins in order to design selective antiviral
compounds. DiGiovanni leads the
research on the molecular signaling under-
lying breast cancer and its treatment.
Sartorelli's lab studies the mechanism of
action behind multi-drug resistance and
DNA base methylating and chloroethylat-
ing agents.
DIRECTIONS FOR THE FUTURE
The symposium "New Frontiers in
Molecular Pharmacology" was a celebra-
tion ofthe new areas that exist in pharma-
cological research. Tony Hunter opened
the symposium with a talk entitled
"Signaling by Phosphorylation in the Age
ofGenomics." In 1979 the Hunter lab dis-
covered the phosphorylation of tyrosine
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residues, leading to role of tyrosine kinas-
es in signal transduction and cell growth
and development.
Joan Steitz then discussed SnoRNP
biogenesis in mammalian cells and the
mechanism behind the release of the
snoRNA from the intron before process-
ing. The Steitz lab is interested in the
structure and function of small ribonucle-
oprotein complexes.
Jack Dixon is interested in the inter-
action between bacterial pathogens and
mammalian signal transduction systems.
He spoke on the Yersina effector YopT, a
protein that is assembled and injected out
of bacteria into mammalian cells. YopT
cleaves Rho GTPases from the membrane
causing disruption of the actin cytoskele-
ton in host cells.
Bob Weinberg provided insight to the
group on his labs research on telomerase,
an enzyme that cleaves the telomeres at
the end of chromosomes in cancer cells.
This enzyme is a target in cancer therapy
because the preservation of the telomeres
in the cancer cells allow for immortalized
proliferation.
Joseph Goldstein, recipient of the
1985 Nobel Prize with Michael Brown for
their discoveries concerning the regulation
ofcholesterol metabolism, spoke about his
research on regulated intramembrane pro-
teolysis. Together, Dr. Brown and
Goldstein discovered that cell surface
receptors mediate the uptake oflow-densi-
ty lipoprotein and their research has led to
treatment and prevention of atherosclero-
SiS.
Stuart Schreiber spoke on the need to
use small molecules to understand the
chromatin signaling network. His lab
focuses on development and application of
diversity-oriented organic synthesis and
the development of ChemBank, a suite of
informatic tools and federated databases
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ofchemical genetics.
Yale alumnus Paul Greengard's lec-
ture, "Signal Integration in the Brain," was
a fitting way to wrap up a symposium cel-
ebrating Yale Pharmacology - past and
present. Greengard integrated the story of
dopamine signaling pathways in the cen-
tral nervous system and its application to
major neurological and psychiatric disor-
ders such as Parkinson's disease, schizo-
phrenia, attention deficit hyperactivity dis-
order, and drug abuse. Greengard and his
proteges have beautifully developed the
dopamine story at Yale and Rockefeller
University over the past three decades. In
particular, he focused on a molecule called
Dopamine and cAMPRegulated Phospho-
Protein with molecular weight = 32 kD
(DARPP-32) which is located at a critical
junction point in the integration and differ-
ential regulation of dopamine signaling
pathways. Greengard concluded his talk
with the summary that "DARPP-32 plays
an essential role in mediating the actions
and interactions of numerous neurotrans-
mitters, therapeutic agents and drugs of
abuse in many brain regions, including the
neostriatum, hippocampus, and cerebral
cortex."
With the 21st century comes a need
for academic research in pharmacology to
expand the traditional borders and find
new ways to address biological questions.
"New Frontiers in Molecular
Pharmacology and Medicine" highlighted
a few of the exciting angles that can be
used in order to conquer disease. With a
new chairman, new laboratory space, and
four new assistant professors, the depart-138 Wittmack and Bi: History ofYale pharmacology
ment ofPharmacology at Yale is well pre-
pared to continue making strong contribu-
tions in the field ofpharmacology.
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